<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55149">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388191</url>
  </required_header>
  <id_info>
    <org_study_id>2015P000436</org_study_id>
    <nct_id>NCT02388191</nct_id>
  </id_info>
  <brief_title>Naproxen for Pain Control With Intrauterine Device Insertion</brief_title>
  <official_title>Naproxen for Pain Control With Intrauterine Device Insertion: A Randomized Double-Blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Planned Parenthood League of Massachusetts</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Planned Parenthood League of Massachusetts</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        1. To evaluate whether 550 mg of naproxen sodium reduces pain scores with IUD insertion on
           a 0-10cm visual analogue scale compared to placebo (primary outcome).

        2. To evaluate whether 550 mg of naproxen sodium reduces pain scores with tenaculum
           placement, uterine sounding and post-procedurally on a 0-10 cm visual analog scale
           compared to placebo (secondary outcomes).

        3. To establish if prophylactic naproxen sodium is acceptable for routine use prior to IUD
           insertion.

      Hypothesis: The administration of naproxen sodium, 550mg orally, 1 hour prior to IUD
      insertion will lead to a reduction in pain scores associated with IUD insertion compared to
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain at time of IUD insertion using a 10cm visual analog scale (VAS)</measure>
    <time_frame>Immediately after IUD insertion is complete</time_frame>
    <description>Pain at time of IUD insertion will be measured immediately upon completion of IUD insertion using a 10cm visual analog scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain with tenaculum placement using a 10cm visual analog scale (VAS)</measure>
    <time_frame>Immediately after tenaculum is placed on cervix</time_frame>
    <description>Pain with tenaculum placement will be measured immediately after tenaculum is placed on the cervix using a 10cm visual analog scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain with uterine sounding using a 10cm visual analog scale (VAS)</measure>
    <time_frame>Immediately after uterine sounding</time_frame>
    <description>Pain with uterine sounding will be measured immediately after uterine sounding using a 10cm visual analog scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain 5 minutes after IUD insertion using a 10cm visual analog scale (VAS)</measure>
    <time_frame>Five minutes after IUD insertion is complete</time_frame>
    <description>Pain 5 minutes after IUD insertion will occur five minutes after IUD insertion is complete using a 10cm visual analog scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain 15 minutes after IUD insertion using a 10cm visual analog scale (VAS)</measure>
    <time_frame>Fifteen minutes after IUD insertion is complete</time_frame>
    <description>Pain 15 minutes after IUD insertion will occur 15 minutes after IUD insertion is complete using a 10cm visual analog scale (VAS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Naproxen sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>550 mg naproxen sodium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen sodium</intervention_name>
    <description>550 mg, oral, on day 1. Number of Cycles: 1</description>
    <arm_group_label>Naproxen sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Premenopausal

          -  Presenting for insertion of any IUD type (i.e. Mirena, Paragard, Skyla)

          -  English-speaking or non-English speaking with appropriate translator available

        Exclusion Criteria:

          -  Currently pregnant or pregnant within the last 4 weeks

          -  Not eligible for IUD insertion per PPLM's clinical protocols

          -  Presenting for IUD removal and reinsertion

          -  Any diagnosis of chronic pain (including fibromyalgia, endometriosis, dysmenorrhea,
             irritable bowel syndrome, interstitial cystitis)

          -  Pain medications taken within 12 hours of enrollment

          -  Misoprostol usage within 24 hours of enrollment

          -  Any known allergy or contraindication to non-steroidal anti-inflammatory drugs
             (including active renal disease, active hepatic disease, gastric ulcer disease or
             gastritis, and bleeding disorders)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>PPLM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood League of Massachusetts</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 9, 2016</lastchanged_date>
  <firstreceived_date>March 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Naproxen</keyword>
  <keyword>Intrauterine devices</keyword>
  <keyword>Pain Control</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
